Long-term follow-up of a phase II study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors
机构：[1]Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis andTranslational Research (Ministry of Education/Beijing), Peking University CancerHospital and Institute, Beijing, China[2]Department of Colorectal Surgery, FudanUniversity Shanghai Cancer Center, Shanghai, China[3]Department of Oncology,Affiliated Hospital of Hebei University, Hebei, China河北大学附属医院[4]Department of GynaecologicOncology, Beijing Cancer Hospital, Beijing, China[5]Department of Biological Immunotherapy, Henan Cancer Hospital, Henan, China河南省肿瘤医院[6]Department of GastrointestinalMedical Oncology, Affiliated Cancer Hospital of Harbin Medical University, Harbin,China[7]Department of Gynecologic Oncology, Chongqing University Cancer Hospital,Chongqing, China[8]Department of Gastrointestinal Oncology, The Fifth Medical Centerof Chinese People’s Liberation Army General Hospital, Beijing, China[9]Department ofMedical Oncology, The Second Affiliated Hospital of Zhejiang University School ofMedicine, Zhejiang, Zhejiang, China[10]Department of Oncology, First Affiliated Hospital of Zhejiang University School Of Medicine, Zhejiang, China[11]Department ofAbdominal Oncology, Cancer Hospital of The University of Chinese Academy of Sciences, Beijing, China[12]Department of Oncology, Fujian Medical University UnionHospital, Fujian, China[13]Department of Oncology, The Sixth Affiliated Hospital of SunYat-sen University, Guangzhou, Guangdong, China[14]Department of GynaecologicOncology, Hunan Cancer Hospital, Hunan, China[15]Department of Oncology, Zhongshan Hospital of Fudan University, Shanghai, China[16]Department of GynaecologicOncology, Hubei Cancer Hospital, Hubei, China[17]Clinical Development, BeiGene(Shanghai) Co., Ltd., Shanghai, China[18]Global Statistics and Data Science, BeiGene(Beijing) Co., Ltd., Beijing, China[19]Clinical Biomarker, BeiGene (Beijing) Co., Ltd.,Beijing, China
第一作者机构：[1]Department of Gastrointestinal Oncology, Key Laboratory of Carcinogenesis andTranslational Research (Ministry of Education/Beijing), Peking University CancerHospital and Institute, Beijing, China
推荐引用方式(GB/T 7714)：
J. Li,Y. Xu,A. Zang,et al.Long-term follow-up of a phase II study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors[J].ANNALS OF ONCOLOGY.2023,34:S640-S640.doi:10.1016/j.annonc.2023.09.2196.
APA：
J. Li,Y. Xu,A. Zang,Y. Gao,Q. Gao...&L. Shen.(2023).Long-term follow-up of a phase II study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors.ANNALS OF ONCOLOGY,34,
MLA：
J. Li,et al."Long-term follow-up of a phase II study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors".ANNALS OF ONCOLOGY 34.(2023):S640-S640
医学